PMID- 19609487
OWN - NLM
STAT- MEDLINE
DCOM- 20100126
LR  - 20161125
IS  - 1439-7609 (Electronic)
IS  - 1439-7595 (Linking)
VI  - 19
IP  - 5
DP  - 2009
TI  - Efficacy of tocilizumab and evaluation of clinical remission as determined by 
      CDAI and MMP-3 level.
PG  - 507-12
LID - 10.1007/s10165-009-0203-z [doi]
AB  - Tocilizumab, a biological agent developed in Japan, is a human anti-interleukin-6 
      (anti-IL-6) receptor antibody. Rheumatoid arthritis improves with its use. A 
      remission rate of 59% is attainable, as measured by disease activity score 28 
      (DAS28) in the SAMURAI study. However, in tocilizumab treatment, C-reactive 
      protein (CRP) and erythrocyte sedimentation rate (ESR) levels drop to negative 
      values; therefore we sought to utilize a different index for measuring its 
      efficacy. In order to evaluate the effects of tocilizumab we carried out this 
      study using clinical disease activity index (CDAI), as it is not reliant on blood 
      data and would also allow us to determine which markers are present in remission. 
      Twenty-two patients under treatment with tocilizumab participated in this study. 
      Effects of treatment as well as the remission rate were measured by CDAI and 
      DAS28 3 months after initiation of treatment. IL-6 and matrix metalloproteinase-3 
      (MMP-3) levels were measured at the same time. We studied the clinical efficacy 
      of tocilizumab using DAS28 after treatment; remission as measured by DAS28 was 
      57.1% at 1 year. However, the remission rate as measured by CDAI was only 19.1% 
      at 1 year. CDAI was not only correlated with DAS28, but also other clinical 
      variables, MMP-3, and IL-6. We conclude that CDAI is effective in measuring 
      clinical response to tocilizumab treatment, and that MMP-3 level is as useful as 
      IL-6 level as an indicator.
FAU - Funahashi, Keiko
AU  - Funahashi K
AD  - Department of Clinical Research, Matsubara Mayflower Hospital, 944-25 Fujita, 
      Kato, Hyogo, 673-1462, Japan. keiko-f@kcc.zaq.ne.jp
FAU - Koyano, Satoru
AU  - Koyano S
FAU - Miura, Takako
AU  - Miura T
FAU - Hagiwara, Takafumi
AU  - Hagiwara T
FAU - Okuda, Kosuke
AU  - Okuda K
FAU - Matsubara, Tsukasa
AU  - Matsubara T
LA  - eng
PT  - Journal Article
DEP - 20090717
PL  - England
TA  - Mod Rheumatol
JT  - Modern rheumatology
JID - 100959226
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Interleukin-6)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - I031V2H011 (tocilizumab)
SB  - IM
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antirheumatic Agents/therapeutic use
MH  - Arthritis, Rheumatoid/blood/*drug therapy
MH  - Blood Sedimentation
MH  - Female
MH  - Humans
MH  - Interleukin-6/blood
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Remission Induction
MH  - *Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2009/07/18 09:00
MHDA- 2010/01/27 06:00
CRDT- 2009/07/18 09:00
PHST- 2009/02/03 00:00 [received]
PHST- 2009/06/15 00:00 [accepted]
PHST- 2009/07/18 09:00 [entrez]
PHST- 2009/07/18 09:00 [pubmed]
PHST- 2010/01/27 06:00 [medline]
AID - 10.1007/s10165-009-0203-z [doi]
PST - ppublish
SO  - Mod Rheumatol. 2009;19(5):507-12. doi: 10.1007/s10165-009-0203-z. Epub 2009 Jul 
      17.